Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: Clin Cancer Res. 2019 Apr 5;25(13):3776–3783. doi: 10.1158/1078-0432.CCR-18-1909

Figure 4: Correlative Studies.

Figure 4:

[A] HRK priming of responders versus non-responders. [B] Progression-free survival of the highest quintile of HRK expression versus the rest of the cohort. [C] HRK priming pre and post-KDD treatment. [D] HRK Priming in bortezomib-refractory versus bortezomib-sensitive/naïve patients.